Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1802946 | 0.68 | HTR2A (0.33) | HTR2C | |
| SCHEMBL1802944 | 0.68 | HTR2A (0.33) | HTR2C | |
| SCHEMBL1905703 | 0.68 | HTR2C (0.41) | HTR2CPNMT | |
| SCHEMBL12510589 | 0.68 | HTR2C (0.49) | HTR2C | |
| SCHEMBL12430114 | 0.68 | HTR2C (0.41) | HTR2CPNMT | |
| SCHEMBL1897659 | 0.65 | HTR2C (0.59) | HTR2C | |
| SCHEMBL9278829 | 0.65 | HTR2C (0.59) | HTR2C | |
| Hydrochloric Acid SCHEMBL9672275 | 0.64 | HTR2C (0.57) | HTR2C | |
| SCHEMBL8350640 | 0.63 | — | — | |
| SCHEMBL17209490 | 0.63 | TAAR1 (0.43) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981919-B2 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | ATHERSYS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981919-B2 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | ATHERSYS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| EP-1796663-B1 | TRICYCLIC HETEROARYL PIPERAZINES, PYRROLIDINES AND AZETIDINES AS SEROTONIN RECEPTOR MODULATORS | ATHERSYS INC (US) | 2011-05-04 | — | — | EP | disclosed |
| EP-1796663-A4 | TRICYCLIC HETEROARYL PIPERAZINES, PYRROLIDINES AND AZETIDINES AS SEROTONIN RECEPTOR MODULATORS | ATHERSYS INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090069365-A1 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | BENNANI YOUSSEF L | 2009-03-12 | — | — | US | disclosed |
| US-20090069365-A1 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | BENNANI YOUSSEF L | 2009-03-12 | — | — | US | disclosed |
| US-7423056-B2 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | ATHERSYS, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423056-B2 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | ATHERSYS, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| EP-1796663-A2 | TRICYCLIC HETEROARYL PIPERAZINES, PYRROLIDINES AND AZETIDINES AS SEROTONIN RECEPTOR MODULATORS | Athersys, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006028961-A2 | TRICYCLIC HETEROARYL PIPERAZINES, PYRROLIDINES AND AZETIDINES AS SEROTONIN RECEPTOR MODULATORS | ATHERSYS, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069365-A1 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | HTR5A, HTR2C, HTR2A | HTR2C 2/4885PNMT 102/4885TAAR1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.